Innate and Sobi announce partnership is now effective following completion of closing conditions

• The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions

• Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions.

As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma. Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027.

Under the agreement, Innate is conducting the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma. The TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in Sézary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results.